Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea OKs Gilead’s Sovaldi, All Eyes On Pricing

This article was originally published in PharmAsia News

Executive Summary

South Korea has granted approval to Gilead’s Sovaldi as a therapy for adults with genotype 1, 2, 3 or 4 chronic hepatitis C in combination with other therapies. All eyes are now on whether all four genotypes will be covered by the national health insurance scheme and at what price the drug will be sold in the country, as the company negotiates for reimbursement with the government over the next few months.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts